Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,319,000 | 2,258,000 | 2,991,000 | 3,226,000 | 2,249,000 |
| Receivables | 3,462,000 | 3,766,000 | 3,456,000 | 3,408,000 | 3,385,000 |
| Inventories | 3,959,000 | 3,927,000 | 3,949,000 | 4,021,000 | 4,051,000 |
| Other current assets | 447,000 | 585,000 | 565,000 | 575,000 | 572,000 |
| TOTAL | $12,314,000 | $11,632,000 | $12,297,000 | $12,485,000 | $11,425,000 |
| Non-Current Assets | |||||
| PPE Net | 5,672,000 | 5,573,000 | 5,618,000 | 5,750,000 | 5,622,000 |
| Intangibles | 20,880,000 | 21,341,000 | 22,063,000 | 22,564,000 | 22,410,000 |
| Other Non-Current Assets | 2,893,000 | 2,792,000 | 2,794,000 | 2,679,000 | 2,631,000 |
| TOTAL | $29,445,000 | $29,706,000 | $30,475,000 | $30,993,000 | $30,663,000 |
| Total Assets | $41,758,000 | $41,338,000 | $42,773,000 | $43,479,000 | $42,088,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,580,000 | 2,094,000 | 3,060,000 | 1,672,000 | 1,479,000 |
| Accounts payable and accrued liabilities | 2,371,000 | 2,366,000 | 2,439,000 | 2,602,000 | 2,280,000 |
| Accrued Expenses | 3,603,000 | 3,332,000 | 3,276,000 | 3,382,000 | 3,271,000 |
| Other current liabilities | 5,026,000 | 4,891,000 | 4,755,000 | 4,579,000 | 4,362,000 |
| TOTAL | $13,797,000 | $13,037,000 | $13,792,000 | $12,247,000 | $11,394,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 16,400,000 | 16,547,000 | 16,584,000 | 18,161,000 | 18,495,000 |
| Other Non-Current Liabilities | 4,592,000 | 4,666,000 | 4,565,000 | 4,335,000 | 4,134,000 |
| TOTAL | $21,577,000 | $21,737,000 | $21,438,000 | $23,106,000 | $23,181,000 |
| Total Liabilities | $35,375,000 | $34,774,000 | $35,230,000 | $35,353,000 | $34,576,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,133,050 | 1,132,909 | 1,132,641 | 1,121,094 | 1,120,971 |
| Common Shares | 58,000 | 58,000 | 58,000 | 57,000 | 57,000 |
| Retained earnings | -14,956,000 | -14,519,000 | -13,673,000 | -13,534,000 | -13,870,000 |
| Other shareholders' equity | -2,451,000 | -2,677,000 | -2,510,000 | -2,076,000 | -2,327,000 |
| TOTAL | $6,383,000 | $6,563,000 | $7,543,000 | $8,126,000 | $7,512,000 |
| Total Liabilities And Equity | $41,758,000 | $41,337,000 | $42,773,000 | $43,479,000 | $42,088,000 |